Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Mizuho (NYSE:MFG) has raised its price target on Acadia Pharmaceuticals (NASDAQ:ACAD) to $24.00 from $23.00 while maintaining a Neutral rating following the company’s second-quarter earnings report. According to InvestingPro data, the stock currently trades below its Fair Value, with analyst targets ranging from $15 to $40.
Acadia reported second-quarter Nuplazid sales of $168.5 million, which was in line with consensus expectations of $159.7 million. The company’s Daybue sales reached $96.1 million, exceeding consensus estimates of $93.8 million. The company maintains strong financial health with an "GREAT" rating on InvestingPro, supported by 14.4% revenue growth and a solid balance sheet showing more cash than debt.
Management has raised the low end of its 2025 U.S. total revenue guidance by $15 million to a new range of $1,045-1,095 million. Mizuho noted this midpoint target of $1,070 million appears achievable based on current performance.
The company continues to make progress with its Nuplazid direct-to-consumer campaign and has expanded its Daybue sales force, with initial metrics indicating continued growth for both products.
Despite the price target increase, Mizuho maintained its Neutral rating, citing a balanced risk/reward profile at current levels, while noting the upcoming Phase 3 COMPASS PWS trial readout for ACP-101 in Prader-Willi Syndrome represents additional potential upside not currently factored into their model.
In other recent news, Acadia Pharmaceuticals reported its second-quarter 2025 earnings, exceeding Wall Street expectations. The company achieved an earnings per share (EPS) of $0.16, surpassing the forecasted $0.14, which represents a 14.29% surprise. Revenue for the quarter reached $264.6 million, slightly above the anticipated $262.44 million. The revenue beat was driven by the performance of Acadia’s DAYBUE medication, while sales for its NUPLAZID product were in line with expectations. Following these results, Citizens JMP raised its price target for Acadia Pharmaceuticals from $37 to $38, maintaining a Market Outperform rating. These developments reflect recent positive momentum for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.